Genmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by Analysts
Genmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by Analysts
Shares of Genmab A/S (NASDAQ:GMAB – Get Rating) have been given a consensus recommendation of "Hold" by the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $547.62.
MarketBeat Ratings報告稱，Genmab A/S（納斯達克股票代碼：GMAB — 獲取評級）的股票已被目前報道該股的十二家經紀公司一致建議 “持有”。一位分析師對該股進行了賣出評級，七位分析師給出了持有評級，兩位分析師給出了買入評級。去年發佈該股報告的經紀商的1年平均目標價格爲547.62美元。
Several equities analysts have recently weighed in on GMAB shares. TheStreet raised shares of Genmab A/S from a "c+" rating to a "b" rating in a research report on Wednesday, August 31st. SVB Leerink increased their price objective on shares of Genmab A/S from $30.00 to $31.00 and gave the company a "market perform" rating in a research report on Thursday, August 11th. Morgan Stanley increased their price objective on shares of Genmab A/S from $29.00 to $31.00 and gave the company an "underweight" rating in a research report on Monday, August 15th. HC Wainwright increased their price objective on shares of Genmab A/S from $49.00 to $51.00 and gave the company a "buy" rating in a research report on Monday, August 22nd. Finally, BMO Capital Markets began coverage on shares of Genmab A/S in a research note on Thursday, June 23rd. They issued a "market perform" rating and a $34.73 price target on the stock.
幾位股票分析師最近對GMAB的股票進行了權衡。TheStreet在8月31日星期三的一份研究報告中將Genmab A/S的股票評級從 “c+” 上調至 “b” 評級。SVB Leerink在8月11日星期四的一份研究報告中將Genmab A/S股票的目標股價從30.00美元上調至31.00美元，並將該公司評爲 “市場表現”。摩根士丹利將Genmab A/S股票的目標股價從29.00美元上調至31.00美元，並在8月15日星期一的一份研究報告中將該公司評爲 “減持”。HC Wainwright在8月22日星期一的一份研究報告中將Genmab A/S股票的目標股價從49.00美元上調至51.00美元，並將該公司評爲 “買入”。最後，BMO Capital Markets在6月23日星期四的一份研究報告中開始報道Genmab A/S的股票。他們發佈了 “市場表現” 評級和34.73美元的目標股價。
Genmab A/S Trading Up 0.1 %
Genmab A/S 交易量上漲0.1％
Shares of GMAB opened at $36.46 on Friday. Genmab A/S has a 12 month low of $26.19 and a 12 month high of $47.28. The firm has a fifty day simple moving average of $35.65 and a 200 day simple moving average of $33.88. The stock has a market capitalization of $23.99 billion, a price-to-earnings ratio of 40.51, a PEG ratio of 1.36 and a beta of 0.85.
週五，GMAB的股價開盤價爲36.46美元。Genmab A/S的12個月低點爲26.19美元，爲12個月高點47.28美元。該公司的五十天簡單移動平均線爲35.65美元，200天簡單移動平均線爲33.88美元。該股票的市值爲239.9億美元，市盈率爲40.51，PEG比率爲1.36，beta值爲0.85。
Institutional Investors Weigh In On Genmab A/S
機構投資者關注Genmab A/S
A number of hedge funds have recently made changes to their positions in the stock. Private Capital Group LLC raised its holdings in Genmab A/S by 14.1% in the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company's stock valued at $87,000 after buying an additional 331 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in Genmab A/S by 2.6% in the 4th quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company's stock valued at $569,000 after buying an additional 358 shares during the last quarter. Private Advisor Group LLC raised its holdings in Genmab A/S by 2.0% in the 2nd quarter. Private Advisor Group LLC now owns 20,522 shares of the company's stock valued at $666,000 after buying an additional 403 shares during the last quarter. Cim LLC raised its holdings in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company's stock valued at $1,002,000 after buying an additional 465 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company's stock valued at $219,000 after buying an additional 513 shares during the last quarter. 5.51% of the stock is currently owned by institutional investors and hedge funds.
許多對沖基金最近改變了其股票頭寸。Private Capital Group LLC在第二季度將其在Genmab A/S的持股量提高了14.1％。Private Capital Group LLC在上個季度又購買了331股股票後，現在擁有該公司2677股股票，價值87,000美元。Wetherby Asset Management Inc. 在第四季度將其在Genmab A/S的持股量提高了2.6％。Wetherby Asset Management Inc. 在上個季度又購買了358股股票後，現在擁有該公司14,389股股票，價值56.9萬美元。Private Advisor Group LLC在第二季度將其在Genmab A/S的持股量提高了2.0％。Private Advisor Group LLC在上個季度又購買了403股股票後，現在擁有該公司20,522股股票，價值66.6萬美元。Cim LLC在第一季度將其在Genmab A/S的持股量提高了1.7％。Cim LLC在上個季度又購買了465股股票後，現在擁有該公司27,994股股票，價值1,002,000美元。最後，SG Americas Securities LLC在第一季度將其在Genmab A/S的持股量提高了9.3％。SG Americas Securities LLC在上個季度又購買了513股股票後，現在擁有該公司6,050股股票，價值21.9萬美元。該股票的5.51％目前由機構投資者和對沖基金持有。
About Genmab A/S
關於 Genmab A/S
(Get Rating)
（獲取評分）
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Genmab A/S 主要在丹麥開發用於治療癌症和其他疾病的抗體療法。該公司銷售用於治療多發性骨髓瘤（MM）患者的人類單克隆抗體DARZALEX；用於治療甲狀腺眼病的替普妥單抗；用於治療慢性淋巴細胞白血病（CLL）和多發性硬化症的人類單克隆抗體ofatumurnab；以及用於晚期或轉移性胃癌或食管癌和非小細胞肺癌的Amivantamab。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 免費獲取 StockNews.com 關於 Genmab A/S (GMAB) 的研究報告的副本
- 股市：紅海中的三個力量之島
- 第四季度值得考慮的3家銀行
- MarketBeat：本週回顧 9/12 — 9/16
- 沒有人告訴這三隻股票這是下跌的一週
- 有辦法治癒Teladoc Stock的病嗎？
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Genmab A/S Daily 的新聞和評級 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Genmab A/S及相關公司的最新新聞和分析師評級的簡明每日摘要。